PMID- 10810400
OWN - NLM
STAT- MEDLINE
DCOM- 20000531
LR  - 20221207
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 20
IP  - 2B
DP  - 2000 Mar-Apr
TI  - Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in 
      previously treated patients with advanced non small cell lung cancer. A phase II 
      study and review of the literature.
PG  - 1077-84
AB  - The use of salvage chemotherapy in advanced non small cell lung cancer (NSCLC) is 
      controversial. However, many patients need to be treated in order to achieve 
      relief of their symptoms. Docetaxel (taxotere) is one of the most active drugs 
      for the treatment of advanced NSCLC and several studies have also shown its 
      effectiveness in pretreated patients. In the present study, 23 patients were 
      treated in order to evaluate both the effectiveness and toxicity of the single 
      agent docetaxel. Furthermore, granulocyte-colony stimulating (G-CSF) factor was 
      administered in order to reduce neutropenia related to docetaxel. Docetaxel was 
      administered intravenously at a dose of 100 mg/m2, on day 1, and it was repeated 
      every 3 weeks. G-CSF was administered for primary prophylaxis of neutropenia at 
      the standard dose of 30 mg/day from day 4 to day 10 of each cycle. The treatment 
      was tolerated well and 5 (21.7%) partial responses were obtained. The median time 
      to progression and the median survival time were 3 and 5 months, respectively. 
      The main side effect noted was fatigue, the intensity of which was grade 2 in 
      43.4% of cases and grade 3 in 8.7% of patients, respectively. One patient (4.3%) 
      had grade 4 cutaneous toxicity. No cases of grade 4 neutropenia were reported. In 
      conclusion, docetaxel is active when used for salvage chemotherapy in advanced 
      NSCLC whilst concurrent primary prophylactic administration of granulocyte-colony 
      stimulating factor seems to decrease severe neutropenia.
FAU - Gridelli, C
AU  - Gridelli C
AD  - Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy. 
      cgridelli@sirio-oncology.it
FAU - Frontini, L
AU  - Frontini L
FAU - Barletta, E
AU  - Barletta E
FAU - Rossi, A
AU  - Rossi A
FAU - Barzelloni, M L
AU  - Barzelloni ML
FAU - Scognamiglio, F
AU  - Scognamiglio F
FAU - Guida, C
AU  - Guida C
FAU - Gatani, T
AU  - Gatani T
FAU - Fiore, F
AU  - Fiore F
FAU - De Bellis, M
AU  - De Bellis M
FAU - Marfella, A
AU  - Marfella A
FAU - Manzione, L
AU  - Manzione L
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Taxoids)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 15H5577CQD (Docetaxel)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Phytogenic/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Deoxycytidine/analogs & derivatives/therapeutic use
MH  - Docetaxel
MH  - Drug Administration Schedule
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/adverse effects/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paclitaxel/adverse effects/*analogs & derivatives/therapeutic use
MH  - Survival Analysis
MH  - *Taxoids
MH  - Gemcitabine
RF  - 45
EDAT- 2000/05/16 09:00
MHDA- 2000/06/03 09:00
CRDT- 2000/05/16 09:00
PHST- 2000/05/16 09:00 [pubmed]
PHST- 2000/06/03 09:00 [medline]
PHST- 2000/05/16 09:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2000 Mar-Apr;20(2B):1077-84.